ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
Retrieved on:
Thursday, January 13, 2022
Science, Other Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Other Health, Radiation, Survival, Patient, Research, Glioblastoma, Nuclear medicine, Antigen, ITM, Clinical trial, University, Helmholtz Association, Neuro-Oncology (journal), Protein, XII, CEO, Solution, Cancer, Leadership, Health, Obesity, Malignancy, Intelligence, Traffic barrier, IIT, Prognosis, Diabetes, Allergy, Quality of life, Association, Radiopharmaceutical, Helmholtz Zentrum München, Therapy, Multimedia, Radionuclide, Chronic lung disease, Risk, Neoplasm, Immunotherapy, TRT, Bachelor of Engineering, III, Medical imaging, Pharmaceutical industry, Neurosurgery, Glioblastoma Multiforme, LuCaFab (ITM-31), ITM Isotope Technologies Munich SE, Helmholtz Munich, GLIOBLASTOMA MULTIFORME, LUCAFAB (ITM-31), ITM ISOTOPE TECHNOLOGIES MUNICH SE, HELMHOLTZ MUNICH
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Helmholtz Munich (Helmholtz Zentrum Mnchen) , today announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma.
Key Points:
- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Helmholtz Munich (Helmholtz Zentrum Mnchen) , today announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma.
- ITM and Helmholtz Munich will collaborate to support an upcoming dose-escalation Phase I clinical trial with LuCaFab (ITM-31).
- Steffen Schuster, CEO of ITM comments: We are pleased to continue our collaboration with Helmholtz Munich and to further advance ITMs clinical pipeline.
- Helmholtz Munich has more than 2,500 employees and is headquartered in Neuherberg, north of Munich.